NASH Drug Pipeline & Market Overview, 2020 - Almost 80 Drug Candidates Involved - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Feb 11, 2020--
The “NASH Drug Pipeline and Market Overview” report has been added to ResearchAndMarkets.com’s offering.
Non-alcoholic steatohepatitis (NASH) is a type of non-alcoholic fatty liver disease (NAFLD). NASH is characterized by inflammation in the liver and liver cell damage, which can lead to scarring of the liver (cirrhosis). No medications have been approved specifically for NASH but there are numerous products in development. NASH Drug Pipeline and Market Overview looks at the almost 80 drug candidates for the treatment of this disease in terms of developer, type of drug, phase study, and market entrance estimate.
In addition, the report provides the following data:
In creating its market forecast, the analyst discusses the indicators that needed to be evaluated to create this estimate, commenting on:
Key Topics Covered:
Chapter 1: Executive Summary
Chapter 2: NASH
Chapter 3: Products in Development
Chapter 4: Market Opportunity
For more information about this report visit https://www.researchandmarkets.com/r/gv65fi
View source version on businesswire.com:https://www.businesswire.com/news/home/20200211005771/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2020.
PUB: 02/11/2020 11:18 AM/DISC: 02/11/2020 11:18 AM